Serum Paraprotein Is Associated with Adverse Prognostic Factors and Outcome, across Different Subtypes of Mature B-Cell Malignancies—A Systematic Review by Maria Christina Cox, Fabiana Esposito, Massimiliano Postorino, Adriano Venditti, Arianna Di Napoli

“…The presence of a serum paraprotein (PP) is usually associated with plasma-cell dyscrasias, Waldenstrom Macroglobulinemia/lymphoplasmacytic lymphoma, and cryoglobulinemia. …”
Get full text

Family Aggregation of Hematological Malignancies Discovered from an Acute Myeloid Leukemia Patient with STK11 and THBD Gene Mutation by Nan Zhang, Xiao-juan Miao, Yan-rong Shuai, Hao Yao, Fang-Yi Fan, Yi-lan Liu

“…Here, we report a case of adult female AML patient whose three relatives suffered from hematological malignancies, including Waldenstrom macroglobulinemia, NK/T-cell lymphoma, and angioimmunoblastic T-cell lymphoma. …”
Get full text

Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directions by Anna Wolska-Washer, Anna Wolska-Washer, Tadeusz Robak, Tadeusz Robak

“…Recent clinical trials have found it to demonstrate excellent efficacy and good tolerability in patients with chronic lymphocytic leukemia (CLL), Waldenstrom macroglobulinemia (WM) and mantle cell lymphoma (MCL). …”
Get full text

Bortezomib‐based therapy is effective and well tolerated in frontline and multiply pre‐treated Waldenström macroglobulinaemia including BTKi failures: A real‐world analysis by Jahanzaib Khwaja, Encarl Uppal, Robert Baker, Kajal Trivedi, Ali Rismani, Rajeev Gupta, Ian Proctor, Charalampia Kyriakou, Shirley D'Sa

“…Abstract Waldenström macroglobulinemia (WM) is a rare, incurable low grade lymphoma following a relapsing trajectory. …”
Get full text

The oncogenic human B-cell lymphoma MYD88 L265P mutation genocopies activation by phosphorylation at the Toll/interleukin-1 receptor (TIR) domain by Marthe Minderman, Hildo Lantermans, Carmen van der Zwaan, Arie J. Hoogendijk, Maartje van den Biggelaar, Marie José Kersten, Marcel Spaargaren, Steven T. Pals

“…A somatic L265P mutation within the Toll/interleukin-1 receptor (TIR) domain of MYD88 is found in 90% of Waldenström macroglobulinemia cases and in a significant subset of diffuse large B-cell lymphomas. …”
Get full text

Atypical clinical picture of waldenström’s macroglobulinemia: a difficult path to diagnosis by E. F. Makhnyr’, N. A. Shostak, N. O. Inasaridze, E. V. Chernaya

“…To describe the difficulties of diagnosis of Waldenström macroglobulinemia in a patient with atypical clinical picture.Materials and methods. …”
Get full text

Relevance of Additional Immunohistochemical Markers in the Differential Diagnosis of Small B-Cell Lymphomas: A Case-Control Study by Hale Kıvrak, Seher Yüksel, Can Ateş, Mustafa Merter, Gülşah Kaygusuz, Muhit Özcan, Işınsu Kuzu

“…Expressions were evaluated in 21 chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), 7 follicular lymphoma (FL), 14 nodal marginal zone lymphoma, 17 extranodal marginal zone lymphoma, 55 splenic marginal zone lymphoma, 22 marginal zone lymphoma-not otherwise specified, and 18 lymphoplasmacytic lymphoma/Waldenström macroglobulinemia cases by immunohistochemistry. …”
Get full text

DNA selection by the master transcription factor PU.1 by J. Ross Terrell, Samuel J. Taylor, Amelia L. Schneider, Yue Lu, Tyler N. Vernon, Suela Xhani, Ryan H. Gumpper, Ming Luo, W. David Wilson, Ulrich Steidl, Gregory M.K. Poon

“…Direct readout by Q226 dynamically specifies PU.1’s characteristic preference for purines and explains the pathogenic mutation Q226E in Waldenström macroglobulinemia. The structures also reveal how disruption of Q226 mediates strand-specific inhibition by DNA methylation and the recognition of non-canonical sites, including the authentic binding sequence at the CD11b promoter. …”
Get full text

First-Line Treatment of Waldenström’s Macroglobulinaemia: Considerations Based on the Dutch National Guideline by Karima Amaador, Marie José Kersten, Hein P. J. Visser, Laurens Nieuwenhuizen, Roelandt F. J. Schop, Martine E. D. Chamuleau, Gerjo A. Velders, Monique C. Minnema, Josephine Mathilde Iris Vos

“…Waldenström macroglobulinemia (WM) is a rare B-cell Non-Hodgkin Lymphoma. …”
Get full text

Atypical nontraumatic chylothorax in a monoclonal IgM elevated nodal marginal zone lymphoma: A case report and review of the literature by Lingling Wang, Qian Huang, Jiao Tang, Jun Feng, Yongfen Huang, Jianming Dong, Yuexin Cheng, Hao Xu, Yuqing Miao

“…Nodal Marginal Zone Lymphoma(NMZL) is an indolent lymphoma with a very low clinical incidence and is sometimes difficult to differentiate diagnostically from Lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia (LPL/WM). NMZL with elevated monoclonal immunoglobulin M (IgM) is even rarer. …”
Get full text

Design of Novel IRAK4 Inhibitors Using Molecular Docking, Dynamics Simulation and 3D-QSAR Studies by Swapnil P. Bhujbal, Weijie He, Jung-Mi Hah

“…MyD88 gain-of-function mutations or overexpression of IRAK4 has been implicated in various types of malignancies such as Waldenström macroglobulinemia, B cell lymphoma, colorectal cancer, pancreatic ductal adenocarcinoma, breast cancer, etc. …”
Get full text

Immunotherapy in indolent Non-Hodgkin's Lymphoma by Ghid Amhaz, Ali Bazarbachi, Jean El-Cheikh

“…Subtypes of iNHL include: Follicular lymphoma (FL), Marginal zone lymphoma (MZL), Chronic lymphocytic leukemia/small-cell lymphocytic lymphoma (CLL/SLL), Gastric mucosa-associated lymphoid tissue (MALT) lymphoma, Lymphoplasmacytic lymphoma, Waldenström macroglobulinemia, Nodal marginal zone lymphoma (NMZL), Splenic marginal zone lymphoma (SMZL). …”
Get full text

Design and Rationale of Prolonged Nightly Fasting for Multiple Myeloma Prevention (PROFAST): Protocol for a Randomized Controlled Pilot Trial by David J Lee, Elizabeth K O'Donnell, Noopur Raje, Cristina Panaroni, Robert Redd, Jennifer Ligibel, Dorothy D Sears, Omar Nadeem, Irene M Ghobrial, Catherine R Marinac

“…ObjectiveWe aim to investigate the effects of 4-month prolonged nightly fasting on body composition and tumor biomarkers among individuals with overweight or obesity with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), or smoldering Waldenström macroglobulinemia (SWM). MethodsIndividuals with MGUS, SMM, or SWM aged ≥18 years and a BMI of ≥25 kg/m2 are randomized to either a 14-hour nighttime fasting intervention or a healthy lifestyle education control group. …”
Get full text

MYD88^L265P Detection in IgM Monoclonal Gammopathies: Methodological Considerations for Routine Implementation by Martina Ferrante, Daniela Furlan, Silvia Zibellini, Michela Borriero, Chiara Candido, Nora Sahnane, Silvia Uccella, Elisa Genuardi, Beatrice Alessandria, Benedetta Bianchi, Barbara Mora, Daniele Grimaldi, Irene Defrancesco, Cristina Jiménez, Federica Cavallo, Dario Ferrero, Irene Dogliotti, Michele Merli, Marzia Varettoni, Simone Ferrero, Daniela Drandi

“…Finally, significantly different MYD88^L265P mutational levels observed between Waldenström Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance patients suggest the need for further studies in order to identify possible correlations between mutational levels and risk of progression to Waldenström.…”
Get full text

Trends in risk for therapy-related myelodysplastic syndrome/acute myeloid leukemia after initial chemo/immunotherapy for common and rare lymphoid neoplasms, 2000–2018Research in co... by Lindsay M. Morton, Rochelle E. Curtis, Martha S. Linet, Sara J. Schonfeld, Pragati G. Advani, Nicole H. Dalal, Elizabeth C. Sasse, Graça M. Dores

“…Among patients treated more recently, tMDS/AML risks were significantly higher after CLL/SLL (SIR2000-2005 = 4.8, SIR2012-2017 = 10, Ptrend = 0.0043), significantly lower after Hodgkin (SIR2000-2005 = 15, SIR2012-2017 = 6.3, Ptrend = 0.024) and marginal zone (SIR2000-2005 = 7.5, SIR2012-2017 = 2.3, Ptrend = 0.015) lymphomas, and non-significantly lower after mantle cell lymphoma (SIR2000-2005 = 10, SIR2012-2017 = 3.2, Ptrend = 0.054), lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (SIR2000-2005 = 6.9, SIR2012-2017 = 1.0, Ptrend = 0.067), and plasma cell neoplasms (SIR2000-2005 = 5.4, SIR2012-2017 = 3.1, Ptrend = 0.051). …”
Get full text

Minimal residual disease status improved the response evaluation in patients with Waldenström’s macroglobulinemia by Wenjie Xiong, Wenjie Xiong, Wenjie Xiong, Zanzan Wang, Tingyu Wang, Tingyu Wang, Tingyu Wang, Ying Yu, Ying Yu, Ying Yu, Yanshan Huang, Yanshan Huang, Yanshan Huang, Hao Sun, Hao Sun, Hao Sun, Jiawen Chen, Jiawen Chen, Jiawen Chen, Rui Lyu, Rui Lyu, Rui Lyu, Huijun Wang, Huijun Wang, Huijun Wang, Yuting Yan, Yuting Yan, Yuting Yan, Qi Wang, Qi Wang, Qi Wang, Wei Liu, Wei Liu, Wei Liu, Gang An, Gang An, Gang An, Weiwei Sui, Weiwei Sui, Weiwei Sui, Wenyang Huang, Wenyang Huang, Wenyang Huang, Dehui Zou, Dehui Zou, Dehui Zou, Zhijian Xiao, Zhijian Xiao, Zhijian Xiao, Jianxiang Wang, Jianxiang Wang, Jianxiang Wang, Guifang Ouyang, Lugui Qiu, Lugui Qiu, Lugui Qiu, Shuhua Yi, Shuhua Yi, Shuhua Yi

“…However, the prognostic value of MRD in Waldenström macroglobulinemia (WM) remains unexplored.MethodsWe analyzed 108 newly diagnosed WM patients receiving systematic therapy and assessed for MRD by multiparameter flow cytometry (MFC) using bone marrow samples.ResultsOf the total patients, 34 (31.5%) achieved undetectable MRD (uMRD). …”
Get full text